Top ▲

Prostate cancer

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:790
Name:Prostate cancer
Associated with:9 targets
Database Links
Disease Ontology: DOID:10283
OMIM: 176807

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols
CXCR5
References:  8
GPR160
Comments:  Gene associated with prostate cancer identified by microarray analysis.
References:  2,5
PKR1
References:  7
Mutations:  PKR1 is associated with 2 mutation. Click here for details
Peroxisome proliferator-activated receptor-γ
Comments:  PPARgamma is expressed in human prostate adenocarcinomas and cell lines derived from human prostate tumors.
References:  6
Androgen receptor
Comments:  Mutations of AR affecting ligand binding as well as gene amplification of AR have been described. Alteration at the receptor level: sometimes increased. Alternative splice variants have been shown to play a role in castration resistant prostate cancer.
References:  1,3-4
TLR1
TLR6
TLR9
regulator of G-protein signaling 8
Role:  RGS8 is one of a number of transcripts identified in the hereditary prostate cancer (HPC1) locus.
References:  9

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖

No ligand related data available for Prostate cancer

References

Show »

1. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL et al.. (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med, 371 (11): 1028-38. [PMID:25184630]

2. Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP. (2007) Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood, 109 (4): 1720-7. [PMID:17068154]

3. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J et al.. (2015) Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol, 67 (1): 53-60. [PMID:24882673]

4. Linja MJ, Visakorpi T. (2004) Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol, 92 (4): 255-64. [PMID:15663988]

5. Mudipalli A, Owen RD, Preston RJ. (2005) The effect of arsenicals on ultraviolet-radiation-induced growth arrest and related signaling events in human keratinocytes. Int J Oncol, 27 (3): 769-78. [PMID:16077927]

6. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. (2000) Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA, 97 (20): 10990-5. [PMID:10984506]

7. O'Hayre M, Vázquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, Gutkind JS. (2013) The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer, 13 (6): 412-24. [PMID:23640210]

8. Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LW, Didier PJ, Grizzle WE, Lillard Jr JW. (2009) Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer, 125 (10): 2288-95. [PMID:19610059]

9. Sood R, Bonner TI, Makalowska I, Stephan DA, Robbins CM, Connors TD, Morgenbesser SD, Su K, Faruque MU, Pinkett H et al.. (2001) Cloning and characterization of 13 novel transcripts and the human RGS8 gene from the 1q25 region encompassing the hereditary prostate cancer (HPC1) locus. Genomics, 73 (2): 211-22. [PMID:11318611]